The impact of the COVID-19 coronavirus pandemic on the surgical management of gynecological cancers: Analysis of the multicenter database of the French SCGP and the FRANCOGYN group.
Borderline tumor
COVID-19
Cancer of vulva
Cancers
Cervical cancer
Endometrial cancer
Gynecologic
Ovarian cancer
Pandemic
Pelvic
SARS-CoV-2
VIRUS
Women
Journal
Journal of gynecology obstetrics and human reproduction
ISSN: 2468-7847
Titre abrégé: J Gynecol Obstet Hum Reprod
Pays: France
ID NLM: 101701588
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
03
01
2021
revised:
15
03
2021
accepted:
23
03
2021
pubmed:
1
4
2021
medline:
24
9
2021
entrez:
31
3
2021
Statut:
ppublish
Résumé
The coronavirus SARS-CoV-2 (COVID-19) pandemic has put tremendous pressure on the French healthcare system. Almost all hospital departments have had to profoundly modify their activity to cope with the crisis. In this context, the surgical management of cancers has been a topic of debate as care strategies were tailored to avoid any delay in treatment that could be detrimental to patient wellbeing while being careful not to overload intensive care units. The primary objective of this study was to observe changes in the surgical management of pelvic cancers during the COVID-19 pandemic in France. This study analyzed data from the prospective multi-center cohort study conducted by the French Society for Pelvic and Gynecological Surgery (SCGP) with methodological support from the French (FRANCOGYN) Group. All members of the SCGP received by e-mail a link allowing them to include patients who were scheduled to undergo gynecological carcinologic surgery between March 16th 2020 and May 11th 2020. Demographic data, the characteristics of cancers and the impact of the crisis in terms of changes to the usual recommended coarse of care were collected. A total of 181 patients with a median age 63 years were included in the cohort. In total, 31 patients had cervical cancer, 76 patients had endometrial cancer, 52 patients had ovarian or tubal cancer, 5 patients had a borderline tumor of the ovary, and 17 patients had vulvar cancer. During the study period, the care strategy was changed for 49 (27%) patients with postponed for 35 (19.3%) patients, and canceled for 7 (3.9%) patients. Surgical treatment was maintained for 139 (76.8%) patients. Management with neoadjuvant chemotherapy was offered to 19 (10,5%) patients and a change in surgical choice was made for 5 (2,8%) patients. In total, 8 (4,4%) patients tested positive for COVID-19. Data also shows a greater number of therapeutic changes in cases of ovarian cancer as well as a cancelation of a lumbo-aortic lymphadenectomy in one patient with cervical cancer. Hospital consultants estimated a direct detrimental impact of the COVID-19 pandemic for 39 patients, representing 22% of gynecological cancers. This study provided observational data of the impact of the COVID-19 health crisis on the surgical management of gynecological cancers.
Identifiants
pubmed: 33789183
pii: S2468-7847(21)00071-4
doi: 10.1016/j.jogoh.2021.102133
pmc: PMC8004475
pii:
doi:
Types de publication
Historical Article
Journal Article
Multicenter Study
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
102133Informations de copyright
Copyright © 2021 Elsevier Masson SAS. All rights reserved.
Références
Gynecol Obstet Fertil Senol. 2020 Nov;48(11):777-783
pubmed: 33010487
Lancet Oncol. 2020 May;21(5):619-621
pubmed: 32220659
Cancer Discov. 2020 Jul;10(7):935-941
pubmed: 32357994
Int J Gynecol Cancer. 2020 Aug;30(8):1101-1107
pubmed: 32513664
Pan Afr Med J. 2019 Jul 26;33:254
pubmed: 31692805